<b>Conclusion</b>: This study establishes CLDN1 as a promising therapeutic target in CRC and reveals that disrupting the CLDN1/CD81 axis might represent a novel treatment strategy. This evidence concerns the gene CLDN1 and colorectal carcinoma.